CN113117054A - 治疗和预防心脑血管疾病的中药组合物及其制备方法 - Google Patents
治疗和预防心脑血管疾病的中药组合物及其制备方法 Download PDFInfo
- Publication number
- CN113117054A CN113117054A CN202110604427.2A CN202110604427A CN113117054A CN 113117054 A CN113117054 A CN 113117054A CN 202110604427 A CN202110604427 A CN 202110604427A CN 113117054 A CN113117054 A CN 113117054A
- Authority
- CN
- China
- Prior art keywords
- parts
- cerebrovascular diseases
- treating
- traditional chinese
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000026106 cerebrovascular disease Diseases 0.000 title claims abstract description 42
- 208000024172 Cardiovascular disease Diseases 0.000 title claims abstract description 41
- 230000002526 effect on cardiovascular system Effects 0.000 title claims abstract description 38
- 239000000203 mixture Substances 0.000 title claims abstract description 31
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 239000003814 drug Substances 0.000 claims abstract description 73
- 235000002722 Dioscorea batatas Nutrition 0.000 claims abstract description 22
- 235000006536 Dioscorea esculenta Nutrition 0.000 claims abstract description 22
- 240000001811 Dioscorea oppositifolia Species 0.000 claims abstract description 22
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 claims abstract description 22
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 claims abstract description 22
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 21
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 21
- 229940086319 nattokinase Drugs 0.000 claims abstract description 19
- 108010073682 nattokinase Proteins 0.000 claims abstract description 19
- 241000361919 Metaphire sieboldi Species 0.000 claims abstract description 18
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims abstract description 17
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims abstract description 17
- 235000009685 Crataegus X maligna Nutrition 0.000 claims abstract description 17
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims abstract description 17
- 235000009486 Crataegus bullatus Nutrition 0.000 claims abstract description 17
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims abstract description 17
- 235000009682 Crataegus limnophila Nutrition 0.000 claims abstract description 17
- 235000004423 Crataegus monogyna Nutrition 0.000 claims abstract description 17
- 235000002313 Crataegus paludosa Nutrition 0.000 claims abstract description 17
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims abstract description 17
- 244000020518 Carthamus tinctorius Species 0.000 claims abstract description 16
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims abstract description 16
- 244000077995 Coix lacryma jobi Species 0.000 claims abstract description 16
- 240000001417 Vigna umbellata Species 0.000 claims abstract description 15
- 235000006545 Ziziphus mauritiana Nutrition 0.000 claims abstract description 15
- 235000008529 Ziziphus vulgaris Nutrition 0.000 claims abstract description 15
- 235000011453 Vigna umbellata Nutrition 0.000 claims abstract description 14
- 244000126002 Ziziphus vulgaris Species 0.000 claims abstract description 14
- 239000002994 raw material Substances 0.000 claims abstract description 7
- 235000012874 Phaseolus calcaratus Nutrition 0.000 claims abstract description 5
- 240000000171 Crataegus monogyna Species 0.000 claims abstract 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 28
- 239000002775 capsule Substances 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 14
- 238000001816 cooling Methods 0.000 claims description 13
- 238000002156 mixing Methods 0.000 claims description 12
- 238000000855 fermentation Methods 0.000 claims description 11
- 230000004151 fermentation Effects 0.000 claims description 11
- 238000010438 heat treatment Methods 0.000 claims description 8
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 6
- 238000010298 pulverizing process Methods 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 5
- 210000000582 semen Anatomy 0.000 claims description 5
- 238000009835 boiling Methods 0.000 claims description 4
- 238000001704 evaporation Methods 0.000 claims description 4
- 238000000227 grinding Methods 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 238000007873 sieving Methods 0.000 claims description 4
- 230000001954 sterilising effect Effects 0.000 claims description 4
- 238000011049 filling Methods 0.000 claims description 3
- 238000011081 inoculation Methods 0.000 claims description 2
- 239000002131 composite material Substances 0.000 claims 3
- 230000000694 effects Effects 0.000 abstract description 39
- 210000000952 spleen Anatomy 0.000 abstract description 34
- 239000008280 blood Substances 0.000 abstract description 26
- 210000002784 stomach Anatomy 0.000 abstract description 26
- 210000004369 blood Anatomy 0.000 abstract description 25
- 230000017531 blood circulation Effects 0.000 abstract description 17
- 206010062717 Increased upper airway secretion Diseases 0.000 abstract description 12
- 208000026435 phlegm Diseases 0.000 abstract description 12
- 208000007536 Thrombosis Diseases 0.000 abstract description 9
- 230000001737 promoting effect Effects 0.000 abstract description 9
- 238000005728 strengthening Methods 0.000 abstract description 7
- 208000037260 Atherosclerotic Plaque Diseases 0.000 abstract description 6
- 210000004204 blood vessel Anatomy 0.000 abstract description 5
- 241000243684 Lumbricus Species 0.000 abstract 1
- 241001092040 Crataegus Species 0.000 description 12
- 235000009508 confectionery Nutrition 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- 229940079593 drug Drugs 0.000 description 8
- 235000019197 fats Nutrition 0.000 description 7
- 210000001124 body fluid Anatomy 0.000 description 6
- 239000010839 body fluid Substances 0.000 description 6
- 210000001715 carotid artery Anatomy 0.000 description 6
- 238000002604 ultrasonography Methods 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 5
- 208000029078 coronary artery disease Diseases 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 208000031226 Hyperlipidaemia Diseases 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 235000012054 meals Nutrition 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 206010003210 Arteriosclerosis Diseases 0.000 description 3
- 206010067116 Carotid arteriosclerosis Diseases 0.000 description 3
- 108010088842 Fibrinolysin Proteins 0.000 description 3
- 206010020710 Hyperphagia Diseases 0.000 description 3
- 201000009594 Systemic Scleroderma Diseases 0.000 description 3
- 206010042953 Systemic sclerosis Diseases 0.000 description 3
- 208000031971 Yin Deficiency Diseases 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 231100000957 no side effect Toxicity 0.000 description 3
- 235000020830 overeating Nutrition 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- 206010008479 Chest Pain Diseases 0.000 description 2
- 206010008469 Chest discomfort Diseases 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 229920000715 Mucilage Polymers 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 206010040026 Sensory disturbance Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 208000031975 Yang Deficiency Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000001174 ascending effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 229940012957 plasmin Drugs 0.000 description 2
- 235000021251 pulses Nutrition 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 208000030814 Eating disease Diseases 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- 206010016946 Food allergy Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019452 Hemianopia Diseases 0.000 description 1
- 208000007460 Hemianopsia Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010031123 Orthopnoea Diseases 0.000 description 1
- 208000004327 Paroxysmal Dyspnea Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 235000010711 Vigna angularis Nutrition 0.000 description 1
- 240000000038 Ziziphus mauritiana Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229940001501 fibrinolysin Drugs 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 235000013557 nattō Nutrition 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 206010029864 nystagmus Diseases 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 208000012144 orthopnea Diseases 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229940068984 polyvinyl alcohol Drugs 0.000 description 1
- 208000023482 precordial pain Diseases 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 235000020046 sherry Nutrition 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 235000019590 thick flavour Nutrition 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8998—Hordeum (barley)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21062—Subtilisin (3.4.21.62)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Nutrition Science (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
Abstract
本发明属于中药制剂技术领域,具体涉及一种治疗和预防心脑血管疾病的中药组合物及其制备方法。所述的治疗心脑血管疾病的中药组合物,包括以下重量份数的原料:麦芽10‑60份,山药5‑15份,山楂5‑15份,红花2‑8份,赤小豆10‑20份,大枣5‑15份,薏苡仁2‑10份,纳豆激酶10‑40份,地龙蛋白2‑10份。本发明的治疗和预防心脑血管疾病的中药组合物,采用活血化瘀、祛浊祛湿的中药方剂,达到了健脾和胃,化痰降脂,去动脉粥样硬化斑块之功效,并在中医药理基础上又加入了纳豆激酶和地龙蛋白,溶解血栓,软化血管,改善血液循环,对心脑血管疾病具有较好的治疗效果。
Description
技术领域
本发明属于中药制剂技术领域,具体涉及一种治疗和预防心脑血管疾病的中药组合物及其制备方法。
背景技术
心脑血管疾病是心脏血管和脑血管疾病的统称,由于高脂血症、血液黏稠、动脉粥样硬化、高血压等所导致的心脏、大脑及全身组织发生的缺血性或出血性疾病。心脑血管疾病是一种严重威胁人类特别是50岁以上中老年人健康的常见病,具有高患病率、高致残率和高死亡率的特点。
其中心血管疾病常见症状有:心悸、气短、端坐呼吸、夜间阵发性呼吸困难、胸骨后的压迫性或紧缩性疼痛、胸闷不适、水肿、发绀、晕厥、咳嗽咯血、虚弱、嗳气、上腹痛、恶心、呕吐;左后背痛、左手臂痛等。脑血管疾病常见症状有:可有偏瘫、偏身感觉障碍、偏盲、失语;或者交叉性瘫痪、交叉性感觉障碍、外眼肌麻痹、眼球震颤、吞咽困难、共济失调、眩晕等;或肢体无力、麻木,面部、上下肢感觉障碍;单侧肢体运动不灵活;语言障碍,说话不利索;记忆力下降;看物体突然不清楚;或眼球转动不灵活;小便失禁;平衡能力失调,站立不稳;意识障碍;头痛或者恶心呕吐;头晕、耳鸣等。
针对心脑血管疾病的病因,常用的治疗方法有保持心态平衡、适当运动、药物治疗、外科治疗、康复治疗等。目前西医的治疗理念主要是:降脂降压、扩张血管、消栓、手术、开刀、“搭桥”、开颅、“支架”等。
应用中医中药治疗心血管疾病,需要根据病因、主症、结合舌苔脉象,通过中医学的病理机制,药物的作用,辩证选择有效的治疗方剂。目前临床上最常见的心血管疾病是冠状动脉粥样硬化性心脏病,而引起的心肌供血不足,出现心慌气短,胸闷,心前区疼痛。中医诊断为“胸痹”、“真心痛”。中医认为导致的主要原因,长期过度劳累,心情不畅,饮食不节损伤心气、心血。气血亏虚,血行迟缓气滞血瘀,不能濡养心肌。一般分为肝肾阴虚、瘀阻心络型及心脾阳虚、痰浊阻络型。肝肾阴虚、瘀阻心络型,采用滋养肝肾、活血祛瘀通络的方法进行治疗;心脾阳虚、痰浊阻络型,采取补养心脾,活血化瘀通络的方法。
发明内容
本发明解决的技术问题是:提供一种治疗和预防心脑血管疾病的中药组合物,采用活血化瘀、祛浊祛湿的中药方剂,达到了健脾和胃,化痰降脂,去动脉粥样硬化斑块之功效,并在中医药理基础上又加入了纳豆激酶和地龙蛋白,溶解血栓,软化血管,改善血液循环,对心脑血管疾病具有较好的治疗效果。
本发明所述的治疗心脑血管疾病的中药组合物,包括以下重量份数的原料:
麦芽10-60份,山药5-15份,山楂5-15份,红花2-8份,赤小豆10-20份,大枣5-15份,薏苡仁2-10份,纳豆激酶10-40份,地龙蛋白2-10份。
优选地,所述治疗心脑血管疾病的中药组合物,包括以下重量份数的原料:
麦芽20-50份,山药10-15份,山楂5-10份,红花2-5份,赤小豆10-15份,大枣8-10份,薏苡仁2-5份,纳豆激酶20-30份,地龙蛋白2-5份。
进一步优选地,所述治疗心脑血管疾病的中药组合物,包括以下重量份数的原料:
麦芽35份,山药10份,山楂10份,红花5份,赤小豆15份,大枣10份,薏苡仁5份,纳豆激酶30份,地龙蛋白5份。
本发明的中药组合物方剂药理如下:
麦芽:行气消食,健脾开胃,甘、平,归脾、胃经。
山药:补脾养胃,生津益肺,补肾涩精,甘、平,归脾、肺、肾经。
山楂:消食健胃,行气散瘀,酸、甘、微温,归脾、胃、肝经。
红花:活血通经,散瘀止痛,辛、温,归心、肝经。
赤小豆:利水消肿,甘、酸、平,归心、小肠经。
大枣:补中益气,养血安神,甘、温,归脾、胃经。
薏苡仁:健脾渗湿,除痹止泻,清热排脓,甘温凉,归脾、胃、肺经。
纳豆激酶:是在纳豆发酵过程中产生的一种丝氨酸蛋白酶,具有溶解血栓,降低血粘度,改善血液循环,软化和增加血管弹性等作用。
地龙蛋白:具有溶栓作用,其有效成分是由纤溶激活蛋白接力产生纤溶酶。这种纤溶酶能抑制血小板聚集、抗凝、降低血粘度,从而阻止血栓形成。
中医治疗心脑血管疾病,是使用传统中医理论中药方剂,对心脑血管疾病进行治疗和调理。中医认为,心脑血管疾病主要是肝胃阴亏,气血亏虚,脾胃运化功能差,痰浊凝滞,瘀血阻络所导致的,因此在治疗上侧重于采用活血化瘀、祛浊祛湿的中药。
本方适应临床上较为常见的痰浊阻遏症,气滞血瘀症。本证的病因、病机、大多由于饮食失调,无规律,暴饮暴食,嗜酒和经常饱食过度,或过食肥甘厚味,从而损伤脾胃。脾主运化、主升清,胃主收纳、主降浊,“脾主为胃行其津液者也”(《素问·厥论》),脾胃健则津液灌注全身,内而五脏六腑,外而四肢百骸,运行不息,一旦脾胃内分,运化失司,升降枢机失常,胃浊脾湿则生痰,而痰乃津液之变。“脾为生痰之源”,即痰为某些黏稠分泌物的病理产物,正如《素问·经脉别论》所说“食气入胃,浊气归心,淫精于脉”。说明饮食经脾胃作用后,其浓厚滋腻部分归养于心脉,它可以助阳化气而有利,也可以生阴化浊而有害,引起肥胖、高血脂症,形成动脉粥样硬化斑块。
根据上述理论,本发明的中药制剂从健脾养胃、化浊降脂、活血化瘀为方法。方中君药为麦芽,性味甘甜,归脾胃二经,以助胃气上升,运脾气而资健运,能消食降胀,宽中下气,醒脾开胃,益气补虚,为补中有利、利中有补之良品;《药品化义》说“主消麦面食积,癥瘕气结,胸膈胀满,郁结痰涎”,用之为主药,健脾和胃,行气散瘀,消而不伐,翰施中州,促其运化,以杜绝痰浊之源,体现治本之法。臣药山药、薏苡仁,甘平和缓,不燥不赋,能补中益气,健脾渗湿,生津养气;大枣甘温、质润而柔,能补脾益阴,生津养胃,滋养营阴,化生卫气,为补脾益气、扶正达邪之要药,配伍山药能滋助脾土运化精液,辅助君药麦芽以促进代谢,分清化浊之功。赤小豆甘酸凉,性主下行,行壅滞,除水湿,利小便,消肿满,为补中有利趋势药,为佐药。使药山楂酸而甘,性中和,不但消食化积,活血化瘀,还可行瘀滞、通脉络;红花活血通经,散瘀止痛,助山楂之功效。
上述诸药合用,共奏健脾和胃,化痰降脂,去动脉粥样硬化斑块之功效,在中医药理基础上又加入了纳豆激酶和地龙蛋白,效果更好。
本发明所述的治疗和预防心脑血管疾病的中药组合物的制备方法,包括以下步骤:
(1)将配方量的麦芽粉碎后加水,加热至70-80℃,保温3-5h,冷却至常温;
(2)将配方量的山药粉碎后加水,加热至80-100℃,保温3-5h,冷却至常温;
(3)将配方量的赤小豆和大枣粉碎后混合,加水,煮沸1-3h,冷却至常温;
(4)将步骤(1)-(3)冷却后的液体混合,接种酵母菌发酵24-48h,然后蒸发掉水分,得到发酵产物;
(5)将步骤(4)的发酵产物和配方量的山楂、红花、薏苡仁、纳豆激酶、地龙蛋白混合,研磨,过110目筛,然后灭菌,制粒,制成胶囊或片剂。
步骤(1)中,麦芽与水的质量比为1:30-80。
步骤(2)中,山药与水的质量比为1:30-80。
步骤(3)中,赤小豆和大枣与水的质量比为1:30-80。
步骤(4)中,酵母菌的接种量为0.5-3g/L。
步骤(5)中,采用零号胶囊进行充填,胶囊的药物含量为0.5g/粒。
步骤(5)中,制片时,在药物中加入辅料,压片制得片剂,片剂的规格为0.8g/片,其中每片含有0.5g药物。
所添加的辅料为药物制片的常规辅料,例如山梨糖醇、麦芽糊精、聚乙烯醇、羟甲基纤维素、硬脂酸镁等。
在服用时,每日3次,每次4粒(片),饭前温水吞服,对蛋白质过敏者忌服。
通过对麦芽、山药、赤小豆和大枣进行加水加热,可以分别提取出麦芽糖、山药多糖粘液质、蛋白质及多糖,再混合进行发酵,能够更好地起到健脾养胃、化浊降脂、活血化瘀的作用。
与现有技术相比,本发明具有以下有益效果:
本发明的治疗和预防心脑血管疾病的中药组合物,采用活血化瘀、祛浊祛湿的中药方剂,达到了健脾和胃,化痰降脂,去动脉粥样硬化斑块之功效,无毒副作用,并在中医药理基础上又加入了纳豆激酶和地龙蛋白,溶解血栓,软化血管,改善血液循环,对心脑血管疾病具有较好的治疗效果,有效率达到90%以上。
具体实施方式
以下结合实施例对本发明作进一步描述。以下内容仅为本发明的具体实施例,不能被认为用于限定对本发明的实施例范围。
实施例1
按以下方剂制备治疗和预防心脑血管疾病的中药组合物胶囊:
麦芽35份,山药10份,山楂10份,红花5份,赤小豆15份,大枣10份,薏苡仁5份,纳豆激酶30份,地龙蛋白5份。
制备方法如下:
(1)将配方量的麦芽粉碎后,加入其重量50倍水,加热至80℃,保温4h,冷却至常温;
(2)将配方量的山药粉碎后,加入其重量50倍水,加热至90℃,保温4h,冷却至常温;
(3)将配方量的赤小豆和大枣粉碎后混合,加入其重量50倍水,煮沸1.5h,冷却至常温;
(4)将步骤(1)-(3)冷却后的液体混合,按1g/L接种酵母菌,发酵24h,然后蒸发掉水分,得到发酵产物;
(5)将步骤(4)的发酵产物和配方量的山楂、红花、薏苡仁、纳豆激酶、地龙蛋白混合,研磨,过110目筛,然后灭菌,制粒,采用零号胶囊进行充填,制得治疗和预防心脑血管疾病的中药组合物胶囊,命名为“雪立清胶囊”,胶囊的药物含量为0.5g/粒。
实施例2
按以下方剂制备治疗和预防心脑血管疾病的中药组合物胶囊:
麦芽50份,山药5份,山楂10份,红花5份,赤小豆5份,大枣10份,薏苡仁5份,纳豆激酶10份,地龙蛋白2份。
制备方法与实施例1相同。
实施例3
按实施例1的方剂制备治疗和预防心脑血管疾病的中药组合物片剂,制备方法如下:
制备方法如下:
(1)将配方量的麦芽粉碎后,加入其重量60倍水,加热至70℃,保温5h,冷却至常温;
(2)将配方量的山药粉碎后,加入其重量60倍水,加热至100℃,保温3h,冷却至常温;
(3)将配方量的赤小豆和大枣粉碎后混合,加入其重量60倍水,煮沸2h,冷却至常温;
(4)将步骤(1)-(3)冷却后的液体混合,按1.5g/L接种酵母菌,发酵30h,然后蒸发掉水分,得到发酵产物;
(5)将步骤(4)的发酵产物和配方量的山楂、红花、薏苡仁、纳豆激酶、地龙蛋白混合,研磨,过110目筛,然后灭菌,制粒,在药物中加入辅料,压片,制得治疗和预防心脑血管疾病的中药组合物片剂,命名为“雪立清片”,片剂的规格为0.8g/片,其中每片含有0.5g药物。
实施例4
按以下方剂制备治疗和预防心脑血管疾病的中药组合物片剂:
麦芽40份,山药8份,山楂8份,红花5份,赤小豆10份,大枣15份,薏苡仁8份,纳豆激酶20份,地龙蛋白5份。
制备方法与实施例3相同。
实施例1制备的“雪立清胶囊”在一家医院进行临床试验:
(1)病例选择:
共10例,男性5例,女性5例,年龄最大的73岁,年龄最小的40岁,其中冠心病合并脑梗塞的有5例,高血压合并冠心病的有3例,高血压伴有高血脂的有2例。
(2)治疗方法及时间:
饭前服用雪立清胶囊,每次4粒,每日3次,温水吞服,连续服用2个月。
(3)症状及疗效检查方法:
现代医学研究证明颈动脉硬化情况是全身的硬化窗口,因此采用颈动脉彩超检查颈部动脉内血液流动、有无颈部动脉硬化、血栓形成等异常;对每位患者在服药前后采用颈动脉彩超检查,以判定症状和疗效。
(4)疗效判定:
痊愈:班块完全消失;
显效:斑块消失50%以上或者一侧斑块完全消失;
有效:斑块减小10%以上;
无效:斑块减小低于10%。
(5)治疗效果:
10例病例中总有效9例,有效率95%;其中治愈3例,显效2例,有效4例,无效1例。
(6)副作用:
服药期间10例病例均未出现副作用。
(7)说明:
以上10例病例临床试验均在春节期间,1例无效病例可能与春节期间饮食有关。
实施例3制备的“雪立清片”在1家医院进行临床试验:
(1)病例选择:
共10例,男性4例,女性6例,年龄最大的83岁,年龄最小的50岁,其中高血压合并冠心病的有4例,脑梗塞后遗症的有1例,单纯冠心病的有2例,患高脂血病、缺血性脑血管病的有1例,糖尿病合并冠心病的有2例。
(2)治疗方法及时间:
饭前服用雪立清片,每次4粒,每日3次,温水吞服,连续服用2个月。
(3)症状及疗效检查方法:
现代医学研究证明颈动脉硬化情况是全身的硬化窗口,因此采用颈动脉彩超检查颈部动脉内血液流动、有无颈部动脉硬化、血栓形成等异常;对每位患者在服药前后采用颈动脉彩超检查,以判定症状和疗效。
(4)疗效判定:
痊愈:班块完全消失;
显效:斑块消失50%以上或者一侧斑块完全消失;
有效:斑块减小10%以上;
无效:斑块减小低于10%。
(5)治疗效果:
10例病例中总有效10例,有效率100%;其中治愈2例,显效3例,有效5例,无效0例。
(6)副作用:
服药期间10例病例均未出现副作用。
(7)说明:
以上10例病例临床试验均在春节期间,其中有2例血脂升高,可能与春节期间饮食有关。
将实施例1和实施例3制备的“雪立清胶囊”和“雪立清片”在另一家医院同时进行临床试验:
(1)病例选择:
总病例数为68例,其中男性39例,女性29例,年龄最大的82岁,年龄最小的40岁,均有颈部动脉硬化斑块。
(2)治疗方法及时间:
饭前服用雪立清胶囊或雪立清片,每次4粒,每日3次,温水吞服,连续服用2个月。
(3)症状及疗效检查方法:
现代医学研究证明颈动脉硬化情况是全身的硬化窗口,因此采用颈动脉彩超检查颈部动脉内血液流动、有无颈部动脉硬化、血栓形成等异常;对每位患者在服药前后采用颈动脉彩超检查,以判定症状和疗效。
(4)疗效判定:
痊愈:班块完全消失;
显效:斑块消失50%以上或者一侧斑块完全消失;
有效:斑块减小10%以上;
无效:斑块减小低于10%。
(5)治疗效果:
68例病例中总有效64例,有效率94.12%;其中治愈12例,显效26例,有效33例,无效4例。
(6)副作用:
服药期间68例病例均未出现副作用。
(7)随机抽取其中20名病例(依次编号为1-20),其治疗效果如表1-2所示。
表1服药前后动脉流速评价
表2服药前后硬化斑块评价
从表1-2可以看出,在抽取的20个病例中,服用本发明的中药组合物后,多数患者的颈部动脉硬化斑块均有不同程度的减小,说明本发明的中药组合物对心脑血管疾病具有较好的治疗效果。
Claims (10)
1.一种治疗和预防心脑血管疾病的中药组合物,其特征在于:包括以下重量份数的原料:
麦芽10-60份,山药5-15份,山楂5-15份,红花2-8份,赤小豆10-20份,大枣5-15份,薏苡仁2-10份,纳豆激酶10-40份,地龙蛋白2-10份。
2.根据权利要求1所述的治疗和预防心脑血管疾病的中药组合物,其特征在于:包括以下重量份数的原料:
麦芽20-50份,山药10-15份,山楂5-10份,红花2-5份,赤小豆10-15份,大枣8-10份,薏苡仁2-5份,纳豆激酶20-30份,地龙蛋白2-5份。
3.根据权利要求2所述的治疗和预防心脑血管疾病的中药组合物,其特征在于:包括以下重量份数的原料:
麦芽35份,山药10份,山楂10份,红花5份,赤小豆15份,大枣10份,薏苡仁5份,纳豆激酶30份,地龙蛋白5份。
4.一种权利要求1-3任一项所述的治疗和预防心脑血管疾病的中药组合物的制备方法,其特征在于:包括以下步骤:
(1)将配方量的麦芽粉碎后加水,加热至70-80℃,保温3-5h,冷却至常温;
(2)将配方量的山药粉碎后加水,加热至80-100℃,保温3-5h,冷却至常温;
(3)将配方量的赤小豆和大枣粉碎后混合,加水,煮沸1-3h,冷却至常温;
(4)将步骤(1)-(3)冷却后的液体混合,接种酵母菌发酵24-48h,然后蒸发掉水分,得到发酵产物;
(5)将步骤(4)的发酵产物和配方量的山楂、红花、薏苡仁、纳豆激酶、地龙蛋白混合,研磨,过110目筛,然后制粒,灭菌,制成胶囊或片剂。
5.根据权利要求4所述的治疗和预防心脑血管疾病的中药组合物的制备方法,其特征在于:步骤(1)中,麦芽与水的质量比为1:30-80。
6.根据权利要求4所述的治疗和预防心脑血管疾病的中药组合物的制备方法,其特征在于:步骤(2)中,山药与水的质量比为1:30-80。
7.根据权利要求4所述的治疗和预防心脑血管疾病的中药组合物的制备方法,其特征在于:步骤(3)中,赤小豆和大枣与水的质量比为1:30-80。
8.根据权利要求4所述的治疗和预防心脑血管疾病的中药组合物的制备方法,其特征在于:步骤(4)中,酵母菌的接种量为0.5-3g/L。
9.根据权利要求4所述的治疗和预防心脑血管疾病的中药组合物的制备方法,其特征在于:步骤(5)中,采用零号胶囊进行充填,胶囊的药物含量为0.5g/粒。
10.根据权利要求4所述的治疗和预防心脑血管疾病的中药组合物的制备方法,其特征在于:步骤(5)中,制片时,在药物中加入辅料,压片制得片剂,片剂的规格为0.8g/片,其中每片含有0.5g药物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110604427.2A CN113117054A (zh) | 2021-05-31 | 2021-05-31 | 治疗和预防心脑血管疾病的中药组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110604427.2A CN113117054A (zh) | 2021-05-31 | 2021-05-31 | 治疗和预防心脑血管疾病的中药组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113117054A true CN113117054A (zh) | 2021-07-16 |
Family
ID=76782856
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110604427.2A Pending CN113117054A (zh) | 2021-05-31 | 2021-05-31 | 治疗和预防心脑血管疾病的中药组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113117054A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115105587A (zh) * | 2022-07-01 | 2022-09-27 | 帝龙科技(中山)有限公司 | 一种防治心、脑、肺血管疾病的药物组合物 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103404759A (zh) * | 2013-05-27 | 2013-11-27 | 胡安然 | 一种冠心病患者食用的特殊膳食 |
CN103585523A (zh) * | 2013-11-26 | 2014-02-19 | 淄博开发区亚大制药有限责任公司 | 一种治疗湿浊脾滞型高脂血症的中药制剂 |
CN109077313A (zh) * | 2018-09-19 | 2018-12-25 | 吉林省恒实传食品科技发展有限公司 | 一种降血脂预防心脑血管疾病的健康养生食品及其制备方法 |
-
2021
- 2021-05-31 CN CN202110604427.2A patent/CN113117054A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103404759A (zh) * | 2013-05-27 | 2013-11-27 | 胡安然 | 一种冠心病患者食用的特殊膳食 |
CN103585523A (zh) * | 2013-11-26 | 2014-02-19 | 淄博开发区亚大制药有限责任公司 | 一种治疗湿浊脾滞型高脂血症的中药制剂 |
CN109077313A (zh) * | 2018-09-19 | 2018-12-25 | 吉林省恒实传食品科技发展有限公司 | 一种降血脂预防心脑血管疾病的健康养生食品及其制备方法 |
Non-Patent Citations (1)
Title |
---|
李里特: "《食品原科学》", 30 September 2001, 中国农业出版社 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115105587A (zh) * | 2022-07-01 | 2022-09-27 | 帝龙科技(中山)有限公司 | 一种防治心、脑、肺血管疾病的药物组合物 |
CN115105587B (zh) * | 2022-07-01 | 2024-01-30 | 帝龙科技(中山)有限公司 | 一种防治心、脑、肺血管疾病的药物组合物 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104366636A (zh) | 一种平卧菊三七复合制剂及制备方法及应用 | |
CN111109602A (zh) | 一种适合糖尿病及高血脂肥胖人群的药膳功能性食品 | |
CN106074871A (zh) | 一种治疗高血压、高血脂、糖尿病的中药制剂及制备方法 | |
CN108524673A (zh) | 一种中药组合物及其应用 | |
CN113117054A (zh) | 治疗和预防心脑血管疾病的中药组合物及其制备方法 | |
CN102552779A (zh) | 具有净化人体血液作用的保健中药组合物及其保健制品 | |
CN107320555A (zh) | 一种具有抗疲劳作用的药物组合物及其制备方法和用途 | |
CN101530565B (zh) | 一种治疗糖尿病的中药制剂及其制备方法 | |
CN103830482B (zh) | 一种治疗脑卒中的中药制剂及制备方法 | |
CN106038743A (zh) | 一种降血压冲剂、制备方法及其应用 | |
CN104587304A (zh) | 一种治疗单纯性肥胖的药物及其用途 | |
CN111544477A (zh) | 一种调节性冷淡的组合物、制备方法及含有组合物的药酒 | |
CN112516268A (zh) | 一种治疗产后病的中药组合物及其制备方法 | |
CN112121094A (zh) | 通络活血振雄中药组合物及其在制备勃起功能障碍改善药物中的应用 | |
CN105521473A (zh) | 一种治疗小儿麻痹后遗症的药物及其制备方法 | |
CN105381441A (zh) | 一种用于防治妊娠水肿的中药胶囊剂及制备方法 | |
CN115381906B (zh) | 治疗代谢综合征的中药组合物及其制备方法、用途 | |
CN102988747A (zh) | 一种三刺降三高的冲剂及其制备方法 | |
CN102274442B (zh) | 一种用于治疗痹症的鹿骨酒及其制备方法和应用 | |
CN105497863A (zh) | 治疗急性乳腺炎的中药组合物 | |
CN113599423A (zh) | 一种治疗贫血的中药组合物 | |
Yulan et al. | Analysis Review of Clinical Application Research of Sanwu Beiji Wan | |
CN112220894A (zh) | 一种治疗高血压的组合物及其制备方法 | |
CN114601900A (zh) | 一种幼儿增高健脾益智膏的配方及制备方法 | |
CN116898900A (zh) | 一种药酒、制备方法及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210716 |